Ibrahim Adel Ehab, Al-Harrasi Ahmed, Alamir Samy G, Salman Baher I, Abdelhalim Emad Mahmoud, El-Sayed Heba M
Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, Nizwa 616, Oman.
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said 42511, Egypt.
Analyst. 2025 May 27;150(11):2312-2321. doi: 10.1039/d5an00229j.
In 2019, 94.00 million prevalent cases of benign prostatic hyperplasia (BPH) were reported, accounting for 2.48% of the global population. BPH is a significant urological health concern worldwide, leading to considerable economic burdens. The European and American guidelines for lower urinary tract symptoms were recently updated in 2023/2024, supporting a combination therapy of alpha-1 blockers with phosphodiesterase-5 inhibitors. Moreover, patents describing this combination have been previously reported. In this work, a novel, totally green organic-solvent-free mixed-micellar liquid chromatography method was developed to simultaneously analyze alpha-1 blockers alfuzosin (ALF) and tamsulosin (TMS) and phosphodiesterase-5 inhibitor tadalafil (TAD). Response surface methodology was employed to optimize the critical chromatographic variables, and a design space representing the robustness zone was identified. Separation was achieved on an RP-C18 column (150 × 4.6 mm, 5 μm) using a green mixture of Brij-35 (19.91 mM), SDS (130.00 mM), and sodium dihydrogen phosphate buffer (10.00 mM) at pH 4.65. The flow rate was set at 1.5 mL min, and UV detection was observed at 250, 285 and 214 nm for ALF, TAD and TMS, respectively. The method was validated over a concentration range of 5-100 μg mL for all drugs with detection limits of 0.77, 1.23 and 1.59 μg mL and quantification limits of 2.35, 3.73 and 4.82 μg mL for ALF, TAD and TMS, respectively. The method was applied to determine the content of the analytes in various tablets and other pharmaceutical products. Greenness of the method was assessed using the Analytical GREEnness metric approach (AGREE), and the blueness was assessed using blue applicability grade index (BAGI), with scores of 0.76 and 82.5, respectively. These scores underline the superiority of the proposed procedure over previously reported methods.
2019年,报告的良性前列腺增生(BPH)患病例数达9400万,占全球人口的2.48%。BPH是全球重大的泌尿外科健康问题,会导致相当大的经济负担。欧美下尿路症状指南最近于2023/2024年更新,支持α-1受体阻滞剂与磷酸二酯酶-5抑制剂联合治疗。此外,此前已有描述这种联合用药的专利报道。在本研究中,开发了一种新型的、完全无有机溶剂的混合胶束液相色谱法,用于同时分析α-1受体阻滞剂阿夫唑嗪(ALF)和坦索罗辛(TMS)以及磷酸二酯酶-5抑制剂他达拉非(TAD)。采用响应面法优化关键色谱变量,并确定了代表稳健区域的设计空间。在RP-C18柱(150×4.6 mm,5μm)上进行分离,使用Brij-35(19.91 mM)、SDS(130.00 mM)和磷酸二氢钠缓冲液(10.00 mM)的绿色混合物,pH值为4.65。流速设定为1.5 mL/min,分别在250、285和214 nm处对ALF、TAD和TMS进行紫外检测。该方法在5-100μg/mL的浓度范围内对所有药物进行了验证,ALF、TAD和TMS的检测限分别为0.77、1.23和1.59μg/mL,定量限分别为2.35、3.73和4.82μg/mL。该方法应用于测定各种片剂和其他药品中分析物的含量。使用分析绿色度指标方法(AGREE)评估该方法的绿色度,使用蓝色适用性等级指数(BAGI)评估蓝色度,得分分别为0.76和82.5。这些分数突出了所提出方法相对于先前报道方法的优越性。